In the Iressa Pan-Asia Study (IPASS) [8], EGFR mutations were assessed by use of tumor tissue-derived DNA (n = 91) and cfDNA from pretreatment serum samples (n = 194). The gene discussed is EGFR; the disease is neoplasm.